Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,496,133 papers from all fields of science
Search
Sign In
Create Free Account
ISOSPAGLUMIC ACID
Known as:
N-acetyl-1-aspartylglutamic acid
, N-Acetyl-l-aspartylglutamate
, N-acetyl-aspartyl-glutamic acid
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
12 relations
Broader (6)
Anti-Allergic Agents
Bronchodilator Agents
Dipeptides
Histamine H1 Antagonists
Expand
Narrower (5)
N-acetyl-aspartyl-glutamate
NAAGA sodium salt
Naaxia
ZY 15106
Expand
Spaglumic Acid
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
SURVIVAL ETHICS : CONSEQUENCES FOR APPROPRIATE TECHNOLOGY
C. Verharen
2011
Corpus ID: 27379754
This essay examines critically the demarcation of ethics and science. While its method is theoretical rather than experimental…
Expand
2005
2005
Complement inhibition reduces material-induced leukocyte activation with PEG modified polystyrene beads (Tentagel) but not polystyrene beads.
M. Gorbet
,
M. Sefton
Journal of Biomedical Materials Research. Part A
2005
Corpus ID: 42677114
With isolated leukocytes, inhibiting complement reduced material-induced leukocyte activation (CD11b) with polyethylene glycol…
Expand
2003
2003
[In vitro effects of antiallergic eyedrops on complement activation induced by particulate matter].
C. Blondin
,
B. Cholley
,
N. Haeffner‐cavaillon
,
P. Goldschmidt
Journal Francais d'Ophtalmologie
2003
Corpus ID: 22049486
BACKGROUND Recent decades have been marked by an increasing number of patients suffering from ocular allergic-like symptoms…
Expand
1989
1989
[NAAGA versus disodium cromoglycate in perennial allergic rhinopathy: results of a multicenter study].
H. Gastpar
,
R. Kiehn
,
C. Sieger
,
M. Weibel
Schweizerische Rundschau fur Medizin Praxis…
1989
Corpus ID: 22167032
The efficacy and tolerability of Naaga (the magnesium salt of N-acetyl-aspartyl-glutamate) and of sodium cromoglycate after…
Expand
1988
1988
[NAAGA and cromoglycate. A comparison in the treatment of seasonal allergic rhinitis].
B. Datz
,
C. Sieger
,
M. Weibel
Laryngologie, Rhinologie, Otologie
1988
Corpus ID: 22605412
A multicentre double-blind clinical trial comparing two nasal solutions of naaga (magnesium salt of N-acetyl aspartyl glutamic…
Expand
1988
1988
Naaga und Cromoglycat
B. Datz
,
C. Sieger
,
Marc Weibel
1988
Corpus ID: 71356221
Antihistaminika spielen schon seit vielen Jahren eine wesentliche Rolle in der Behandlung von Heufieber trotz einiger…
Expand
1988
1988
Etude du N-acétyl-aspartyl-glutamate de magnésium sur la provocation bronchique non spécifique au carbachol
P. Rufin
,
M. Benoist
,
J. Brouard
,
J. Luyckx
,
P. Scheinmann
,
J. Paupe
1988
Corpus ID: 53764309
1986
1986
Effects of a new anti-allergic agent: the magnesium salt of N-acetyl-aspartyl-glutamic acid on experimental allergic inflammation of the rabbit eye.
P. Lapalus
,
G. Moulin
,
V. Bayer
,
D. Fredj-Reygrobellet
,
P. Elena
Current Eye Research
1986
Corpus ID: 29544463
We evaluated the efficacy of N-Acetyl-Aspartyl-Glutamic acid (magnesium salt) (NAAGA) eye-drops in preventing the conjunctival…
Expand
1986
1986
[A peptide (a magnesium salt of N-acetyl (alpha, beta)-aspartyl-glutamic acid). Demonstration of the protection against local cellular destruction induced by in situ complement activation].
L. Chevance
,
M. Etievant
Journal de pharmacologie
1986
Corpus ID: 25448290
A peptide of simple chemical structure has demonstrated its efficiency in preventing the large cellular destruction that locally…
Expand
1985
1985
[N-acetyl-aspartylglutamic acid eye drops in allergic-type conjuctivitis. Double-blind comparative clinical study].
M. Bonnet
,
D. Ducournau
,
P. Lumbroso
,
G. Serpin
Journal Francais d'Ophtalmologie
1985
Corpus ID: 25511397
Fifty patients with allergic conjunctivitis were included in a double-blind randomized clinical trial designed to compare the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE